Login / Signup

H 2 inhalation therapy in patients with moderate COVID-19 (H 2 COVID): a prospective ascending-dose phase I clinical trial.

Cordelia IhlJ GiaiM BarbadoA ParisS TouatiJ P AlcarazS TanguyC LeroyA LehmannB DeganoM GavardP BedouchP PaveseA Moreau-GaudryM RoustitFrançois BoucherP CinquinJ P Brion
Published in: Antimicrobial agents and chemotherapy (2024)
This study is registered with ClinicalTrials.gov as NCT04633980.
Keyphrases
  • coronavirus disease
  • sars cov
  • clinical trial
  • respiratory syndrome coronavirus
  • high intensity
  • randomized controlled trial
  • study protocol
  • open label
  • phase ii
  • pulmonary arterial hypertension